Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.
Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.
复制标题
DOI：
10.1177/1470320316656480
复制
发表时间：
2016-10
期刊：
影响因子：
--
通讯作者：
SMILE-4 Working Party
中科院分区：
文献类型：
--
作者：
Borghi C;Omboni S;Novo S;Vinereanu D;Ambrosio G;Ambrosioni E;SMILE-4 Working Party
这是一项前瞻性、随机、双盲心肌梗死生存长期评估（SMILE） 4研究的倾向评分分析，在急性心肌梗死（AMI）合并左心室功能障碍（LVD）患者的心血管原因死亡或住院方面，佐非普利60 mg加乙酰水杨酸（ASA） 100 mg治疗一年的结果优于雷米普利10 mg加ASA。使用逻辑回归模型（QI：最佳风险概况；QV：最差风险概况）将意向治疗人群中的716名患者分为均匀倾向五分位数(Q)。然而，唑非普利在QII、QV，尤其是QIII方面的疗效优于雷米普利（优势比（OR）和95%可信区间：0.43 (0.21-0.87),p<0.05）。这一结果主要归因于心血管住院的风险降低，特别是在QIII中显著（OR: 0.40, 0.19-0.85; p<0.05）。在SMILE-4研究中，倾向分析证实了佐非普利在预防长期心血管结局方面的有效性，无论ami后患者的心血管风险情况如何。
This was a propensity score analysis of the prospective, randomized, double-blind Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study in which one-year treatment with zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg gave superior results compared to ramipril 10 mg plus ASA in terms of death or hospitalization for cardiovascular causes in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction (LVD). A total of 716 patients of the intention-to-treat population were divided into homogeneous propensity quintiles (Q) using a logistic regression model (QI: best risk profile; QV: worst risk profile). Treatment was associated with a similar low rate of major cardiovascular events in any Q. However, the efficacy of zofenopril was better than that of ramipril in QII, QV, and particularly QIII (odds ratio (OR) and 95% confidence interval: 0.43 (0.21–0.87), p<0.05]. This result was primarily attributed to a decrease in the risk of cardiovascular hospitalization, particularly striking in the QIII (OR: 0.40, 0.19-0.85; p<0.05). Mortality rate did not significantly differ between the two treatments in any Q. In the SMILE-4 study the propensity analysis confirmed the efficacy of zofenopril in the prevention of long-term cardiovascular outcomes irrespective of the cardiovascular risk profile of post-AMI patients.
登录
查看更多内容
影响因子：
37.8
作者：
D'Agostino, Ralph B., Jr.
通讯作者：
D'Agostino, Ralph B., Jr.
影响因子：
2.9
作者：
Bugiardini, Raffaele;Eskola, Markku;Nikus, Kjell
通讯作者：
Nikus, Kjell
影响因子：
2.7
作者：
Borghi, Claudio;Ambrosioni, Ettore;Ambrosio, Giuseppe
通讯作者：
Ambrosio, Giuseppe
DOI：
10.7326/0003-4819-127-8_part_2-199710151-00064
发表时间：
1997-10-15
影响因子：
39.2
作者：
Rubin, DB
通讯作者：
Rubin, DB
影响因子：
3.7
作者：
ROSENBAUM, PR;RUBIN, DB
通讯作者：
RUBIN, DB